TIDMEDX 
 
This announcement contains Inside Information as stipulated under the UK 
version of the Market Abuse Regulation No 596/2014 which is part of English law 
by virtue of the European (Withdrawal) Act 2018, as amended.  On publication of 
this announcement via a regulatory information service, this information is 
considered to be in the public domain. 
 
14 November 2022 
 
                             EDX Medical Group Plc 
 
                          (Formerly TECC Capital Plc) 
 
                                ("the Company") 
 
            Admission to trading on AQSE and First Day of Dealings 
 
Highlights 
 
  * Acquisition of EDX Medical Limited for £12m completed 
  * Placing of new shares at 6 pence per share completed raising £1.2m 
  * New Board appointed 
  * Change of name to EDX Medical Group Plc completed 
 
Further to its announcement on 26 October 2022, the Company, now renamed EDX 
Medical Group Plc ("EDX Medical"), has today completed its acquisition of EDX 
Medical Limited. The Company  (TIDM: EDX), which develops digital diagnostic 
products and services for use in testing for cancer, heart disease, neurology 
and infectious diseases, is pleased to announce that 250,833,333 ordinary 
shares of 1 pence each ("Ordinary Shares") are today being admitted to trading 
on the Access Segment of the AQSE Growth Market ("Admission"). 
 
In connection with Admission, the Company has raised £1.2 million through a 
placing of 20,000,000 Ordinary Shares at a price of 6 per share. 
 
In addition, the appointment of the new Board, comprising Jason Holt as 
Chairman, Dr Michael Hudson as Chief Executive, Professor Sir Christopher 
Evans, OBE, as Chief Scientific Officer and Professor Trevor Jones as a 
Non-executive Director has taken effect and the former Directors, Sandy 
Barblett, John Taylor and Donald Stewart have stepped down from the Board with 
effect from Admission. 
 
Further details of each of members of the new Board are set out in the 
Company's announcement of 26 October 2022 and can be found in the Company's 
Admission Document which was published on the same day. 
 
EDX Medical Ltd was founded by Professor Sir Christopher Evans, OBE, a medical 
and life sciences entrepreneur with more than 30 years of experience in the 
sector, specialising in cancer treatments and diagnostics. 
 
Jason Holt, Chairman, stated: "We are proud to be bringing EDX Medical to the 
AQSE Growth Market today as an important part of our strategy to develop a 
substantial digital healthcare business. Initially, we are focusing on cancer 
testing and are building on the expertise and experience of our founder and 
leadership team particularly in relation to the utilisation of advanced 
molecular and genomic testing to improve the detection and treatment of 
cancer." 
 
Dr Mike Hudson, Chief Executive Officer, stated: "We are driving biomedical and 
digital innovation in cancer testing at a time when the need for greater access 
to risk assessment, diagnosis and personalised treatment of cancer has never 
been greater. A key focus of our work is the expansion of advanced tests for 
cancers affecting women." 
 
"Admission to the public market, underscores our confidence in the opportunity 
to deliver the substantial benefits of digital diagnostics over coming years, 
fuelling our growth through organic developments, acquisitions and strategic 
partnerships.". 
 
Information on EDX Medical 
 
EDX Medical develops and validates digitally-enabled diagnostic products and 
services to help predict disease risk, inform clinical decision-making and 
accelerate the development of new medicines in the areas of cancer, heart 
disease, neurology and infectious diseases. 
 
By translating clinical insights into pragmatic solutions combining advanced 
biological and digital technologies, EDX Medical seeks to improve the detection 
of disease risk and personalise disease management, cost-effectively and in a 
timely fashion. The Directors believe that early disease detection and risk 
prediction is the most impactful way of reducing deaths and lowering the future 
costs of healthcare provision globally. 
 
EDX Medical operates a molecular biology and diagnostics laboratory in 
Cambridge, UK, from which it performs research & development (R&D), provides 
testing and genomic sequencing services, undertakes quality assurance and has 
established expertise in the design, development, validation and sourcing of 
diagnostic tests at commercial scale. Key tests performed in this laboratory 
have been audited by the United Kingdom Accreditation Service (UKAS) and 
accredited to ISO 15189. 
 
Further information on the Company can be found at: https:// 
www.edxmedical.co.uk 
 
Total Voting Rights 
 
For the purposes of the Financial Conduct Authority's Disclosure Guidance and 
Transparency Rules, the Company has 250,833,333 Ordinary Shares in issue. This 
figure of 250,833,333 Ordinary Shares may be used by shareholders in the 
Company as the denominator for the calculations by which they will determine if 
they are required to notify their interest in, or a change to their interest 
in, the share capital of the Company under the Financial Conduct Authority's 
Disclosure Guidance and Transparency Rules. 
 
The Directors of the Company accept responsibility for the contents of this 
announcement. 
 
Enquiries: 
 
Company                                       +44 (0)207 710 0020 
Dr Michael Hudson, CEO 
 
AQSE Growth Market Corporate Advisor          +44 (0)20 220 9795 
Peterhouse Capital Limited 
Guy Miller/Mark Anwyl 
 
Public Relations on behalf of the Company     +44 (0)207 710 0020 
Ramsay Smith, Media House International       +44 (0) 7788 414856 
Limited                                       ramsay@mediahouse.co.uk 
 
 
 
END

(END) Dow Jones Newswires

November 14, 2022 02:00 ET (07:00 GMT)

EDX Medical (AQSE:EDX)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024 Click aqui para mais gráficos EDX Medical.
EDX Medical (AQSE:EDX)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024 Click aqui para mais gráficos EDX Medical.